Skip to main content
Top
Published in: Archives of Osteoporosis 1/2022

01-12-2022 | Denosumab | Original Article

Stop the denosumab delay! The effect of implementing an automatic reminder in the electronic medical record

Authors: Adnin Zaman, Micol S. Rothman, Sarah J. Billups

Published in: Archives of Osteoporosis | Issue 1/2022

Login to get access

Abstract

Summary

Delays in denosumab dosing for osteoporosis treatment may lead to rapid bone loss or increased fractures. We assessed the frequency of delayed denosumab dosing before and after the implementation of a structured ordering plan with automated reminders and found that the rate of delayed denosumab dosing was cut in half.

Purpose

The purpose of our study was to assess the frequency of delayed denosumab dosing before and after the implementation of a structured ordering plan with automated reminders.

Methods

We conducted a retrospective chart review of 720 adults with osteoporosis who received at least two denosumab doses within the UCHealth system before and after the plan went into effect.

Results

There was a significant reduction in delayed dosing from 24.0% (PRE) to 12.6% (POST) (p < 0.001) after implementation of the automated reminder. The fraction of delayed denosumab doses due to scheduling issues decreased significantly between PRE and POST time periods (16.4% vs. 3.3%, p = 0.011), while patient-related issues increased from 31.2% to 46.7% (p = 0.041). The rate of provider, medical, and other/unknown issues did not differ between the two time periods. When normalized to patient-years of follow-up, the number of fractures was the same for both groups at 0.016 fractures per patient-year. Fractures in both the PRE and POST groups were related to dosing delays, but the study was not powered to detect the differences in fracture rates between the groups.

Conclusion

Electronic records with automatic reminders can reduce delayed dosing of denosumab and may lead to reductions in fractures associated with delays.
Literature
1.
go back to reference Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed
2.
go back to reference Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523CrossRefPubMed Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523CrossRefPubMed
3.
go back to reference Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929–1930CrossRefPubMed Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929–1930CrossRefPubMed
6.
go back to reference Perri-Moore S, Kapsandoy S, Doyon K, Hill B, Archer M, Shane-McWhorter L, Bray BE, Zeng-Treitler Q (2016) Automated alerts and reminders targeting patients: a review of the literature. Patient Educ Couns 99:953–959CrossRefPubMed Perri-Moore S, Kapsandoy S, Doyon K, Hill B, Archer M, Shane-McWhorter L, Bray BE, Zeng-Treitler Q (2016) Automated alerts and reminders targeting patients: a review of the literature. Patient Educ Couns 99:953–959CrossRefPubMed
7.
go back to reference Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10:152CrossRefPubMedPubMedCentral Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10:152CrossRefPubMedPubMedCentral
8.
go back to reference Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144:115830CrossRefPubMed Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144:115830CrossRefPubMed
Metadata
Title
Stop the denosumab delay! The effect of implementing an automatic reminder in the electronic medical record
Authors
Adnin Zaman
Micol S. Rothman
Sarah J. Billups
Publication date
01-12-2022
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2022
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-022-01065-1

Other articles of this Issue 1/2022

Archives of Osteoporosis 1/2022 Go to the issue